Nanobiotix

Nanobiotix S.a.

Curadigm Sas

Centre National De La Recherche Scientifique

The State University of New York

Universitë De Bordeaux

Curadigm

Laurent Levy

Marie-Edith Meyre

Agnes Pottier

Matthieu Germain

Agnès Pottier

Paras Nath Prasad

Earl Jim Bergey

Laurence Poul

Elsa Borghi

Audrey Darmon

Jérémy Balencie

Abdel Kader Boussaha

Laurence Maggiorella

Agnés Pottier

Julie Marill

Jean-Francois Hochepied

Edouard Andre Panak

Cyril Lorenzato

Celine Berjaud

Pierre Smirnov

Chrit Moonen

Jean-François Hochepied

Edouard André Panak

Annabelle Rouet

Corinne Devaux

Charles Liebow

Marie-edith Meyre

Céline Berjaud

The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant &#x3b5;equal to or above 200, and an insulator material with a dielectric constant &#x3b5;equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.

Nanoparticles for use for treating a neuronal disorder

The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant &#x3b5;equal to or above 200, and an insulator material with a dielectric constant &#x3b5;equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.

The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant &#x3b5;equal to or above (200), and an insulator material with a dielectric constant &#x3b5;equal to or below (100). It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source such as a light source, a magnetic field, or an ultrasound source.

Nanoparticles for use in enhancing brain performances or in treating stress

The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a first biocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle.

Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof

The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.

Pharmaceutical composition, preparation and uses thereof

The present invention relates to the medical field, in particular to the enhancement of brain performances and to the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject when the nanoparticle and/or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant &#x3b5;equal to or above 200, and an insulator material with a dielectric constant &#x3b5;equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.

Nanoparticles for use for enhancing brain performances or for treating stress

The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use for modulating electrical polarization of neurons in a subject, for example for use in prevention or treatment of a neuronal disease in a subject, typically by modulating electrical polarization of neurons in the subject, wherein i) when the nanoparticle or nanoparticles' aggregate is exposed to a light source, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, ii) when the nanoparticle or nanoparticles' aggregate is exposed to a magnetic field, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling magneto-electric transduction or magneto-thermal transduction, iii) when the nanoparticle or nanoparticles' aggregate's surface is exposed to an ultrasound source, the nanoparticle's or nanoparticles' aggregate's material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticles' aggregate is either neutrally charged in the absence of any coating or is coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticles' aggregate. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.

Coated nanoparticles for use for modulating electrical polarization of neurons

The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.

Nanoparticles for use as a therapeutic vaccine

The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with a hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal's intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.

Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof

The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest effectiveness in therapy, prophylaxis or diagnosis. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.

Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis

The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein: i) the nanoparticles and/or nanoparticles of said aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticles and nanoparticle aggregates being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 sof the gel comprising the nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa&#xb7;s and about 1000 Pa&#xb7;s when measured between 20&#xb0; C. and 37&#xb0; C. The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using an X-ray imaging equipment.

Growing community of inventors

Paris, France

Laurent Levy